0001140361-22-030756.txt : 20220824 0001140361-22-030756.hdr.sgml : 20220824 20220824164101 ACCESSION NUMBER: 0001140361-22-030756 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220824 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220824 DATE AS OF CHANGE: 20220824 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 221192014 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 ny20005031x2_8k.htm FORM 8-K
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 
FORM 8-K

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 24, 2022

 
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)


     
Delaware
 001-37568
 26-4231384
 
 
 
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

25B Vreeland Road, Suite 300, Florham Park, NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
 Item 1.01
Entry Into a Material Definitive Agreement.
 
Venture Loan and Security Agreement
 
On August 24, 2022, PDS Biotechnology Corporation (the “Company”), as borrower (the “Borrower”), entered into that certain Venture Loan and Security Agreement (the “Loan and Security Agreement”) by and among Borrower, PDS Operating Corporation, as guarantor (“Guarantor”, including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the “Loan Parties” and each individually a “Loan Party”) , the persons party thereto from time to time as lenders (collectively, the “Lenders”), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself  and the other Lenders (in such capacity, the “Collateral Agent”).
 
Term loan Amounts. The Loan and Security Agreement provides for the following six (6) separate and independent term loans: (a) a term loan in the amount of $7,500,000 (“Loan A”), (b) a term loan in the amount of $10,000,000 (“Loan B”), (c) a term loan in the amount of $3,750,000 (“Loan C”), (d) a term loan in the amount of $3,750,000 (“Loan D”), (e) a term loan in the amount of $5,000,000 (“Loan E”), and (f) a term loan in the amount of $5,000,000 (“Loan F”) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a “Loan” and, collectively, the “Loans”).  Loan A, Loan B, Loan C, and Loan D are committed Loans and shall be made available to Borrower upon entering into the Loan and Security Agreement.  Loan E and Loan F are uncommitted Loans that may be advanced by the Lenders upon their discretion prior to July 31, 2023 upon the satisfaction by Borrower and Guarantor of certain agreed upon conditions precedents. Borrower may only use the proceeds of the Loans for working capital or general corporate purposes.
 
Maturity. Each Loan matures on the forty-eight (48)-month anniversary following the applicable Funding Date (defined as any date on which a Loan is made to or on account of the Borrower under the Loan and Security Agreement) (the “Maturity Date”) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.
 
Interest Rate. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the “prime rate” then in effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month.
 
Amortization. Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the Borrower is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respect Loan (the “Loan Amortization Date”), and continuing thereafter on the first business day of each calendar month through the Maturity Date.
 
Prepayment Premium. The Borrower may, at its option upon at least ten (10) business days’ written notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, three  percent (3%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is twelve (12) months after such Loan Amortization Date, two percent (2%) of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date applicable to such Loan, one percent (1%) of the then outstanding principal balance of such Loan; plus (iii) the outstanding principal balance of such Loan; plus (iv) all other sums, if any, that shall have become due and payable hereunder.  No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated Maturity Date.
Security. The Borrower’s obligations are secured by a security interest in all of the Loan Parties’ respective rights, title, interests, claims and demands in, to and under all of the Loan Parties respective  properties and other assets, subject to limited exceptions and excluding the Loan Parties’ intellectual property.
 
Covenants; Representations and Warranties; Other Provisions. The Loan and Security Agreement contains customary representations, warranties and covenants, including covenants by the Loan Parties limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes.
 
Default Provisions. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment, breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.
 
Warrants

In connection with the entry into the Loan and Security Agreement, the Company has issued to Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants (each, individually, a “Warrant” and, collectively, the “Warrants”) to purchase an aggregate number of shares of the Company’s Common Stock (as defined below) for each Loan as follows: (a) for Loan A an amount that is equal to $300,000 divided by the warrant price for such Warrant, (b) for Loan B an amount that is equal to $400,000 divided by the warrant price for such Warrant, (c) for Loan C an amount that is equal to $150,000 divided by the warrant price for such Warrant, (d) for Loan D an amount that is equal to $150,000 divided by the warrant price for such Warrant, (e) for Loan E an amount that is equal to $200,000 divided by the warrant price for such Warrant, and (f) for Loan F an amount that is equal to $200,000 divided by the warrant price for such Warrant.
 
The Warrants, which are exercisable for an aggregate of 381,625 shares, will be exercisable for a period beginning on the Date of Grant and ending on the earlier of (A) ten (10) years from the Date of Grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in each case, for cash or for marketable securities meeting all of the following requirements: (1) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Securities Act of 1933, as amended, and the Exchange Act, (2) the class and series of shares or other security of the issuer that would be received by the holder of a Warrant in connection with a merger were such holder to exercise or convert such Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, (3) the issuer thereof has a market cap of at least $750,000,000 and (4) such holder would not be restricted by contract or by applicable federal and state securities laws from publicly re-selling, within six (6) months and one day following the closing of such acquisition, all of the issuer’s shares and/or other securities that would be received by such holder in such merger were such holder to exercise or convert a Warrant in full on or prior to the closing of such merger. Each Warrant will be exercisable at a per-share exercise price of $3.6685, which is equal to the 10 day average closing price prior to June 16, 2022, the date on which the term sheet relating to the Loan and Security Agreement was entered into, subject to certain adjustments as specified in the Warrants.
 
The foregoing descriptions of the Loan and Security Agreement and the Warrants are qualified in their entirety by reference to the Loan and Security Agreement and the form of Warrant each of which will be filed as exhibits to the Company’s quarterly report on Form 10-Q for the quarter ending September 30, 2022.
 
Sales Agreement
 
On August 24, 2022, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and BTIG, LLC (each an “Agent” and collectively the “Agents”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.00033 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million (the “Placement Shares”) through or to the Agents, as sales agents or principals. The issuance and sale, if any, of the Placement Shares by the Company under the Sales Agreement is subject to the effectiveness of the Company’s registration statement on Form S-3 (File No. 333-267041), which was filed with the Securities and Exchange Commission on August 24, 2022.
Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Common Stock. The Agents will use commercially reasonable efforts to sell the Placement Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and also has provided the Agents with customary indemnification and contribution rights.
 
The Company is not obligated to make any sales of the Common Stock under the Sales Agreement. The offering of Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.
 
DLA Piper LLP (US), counsel to the Company, has issued a legal opinion relating to the Placement Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.
 
The foregoing description of the Sales Agreement is qualified in its entirety by reference to the full text of the Sales Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 
Item 2.03
Creation of a Direct Financial Obligation or and Obligation under and Off-Balance Sheet Arrangement of a Registrant.
 
The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
 
Item 3.02
Unregistered Sales of Equity Securities.
 
The information provided in Item 1.01 of this Current Report on Form 8-K regarding the Warrants is incorporated by reference into this Item 3.02.

Item 8.01
 Other Events.
 
On August 24, 2022, the Company issued a press release regarding the Loan and Security Agreement. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.
 
Exhibit No.
Description
   
Opinion of DLA Piper LLP (US), dated August 24, 2022.
   
At Market Issuance Sales Agreement dated August 24, 2022 by and between PDS Biotechnology Corporation, B. Riley Securities, Inc., and BTIG, LLC (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed by the Company on August 24, 2022, Reg. No. 333-267041). 
   
Consent of DLA Piper LLP (US) (contained in Exhibit 5.1 above).
   
   
99.1
 		Press Release dated August 24, 2022.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: August 24, 2022
PDS BIOTECHNOLOGY CORPORATION

   

By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name:
Frank Bedu-Addo, Ph.D.
 
Title:
President and Chief Executive Officer 

EX-5.1 2 ny20005031x2_ex5-1.htm EXHIBIT 5.1
Exhibit 5.1

August 24, 2022
 
PDS Biotechnology Corporation
25B Vreeland Road, Suite 300
Florham Park, NJ 07932
 
RE: PDS Biotechnology Corporation Registration Statement on Form S-3
 
Ladies and Gentlemen:
 
We have acted as counsel to PDS Biotechnology Corporation, a Delaware corporation (the “Company”), in connection with the issuance and sale by the Company from time to time of shares of the Company’s common stock, par value $0.00033 per share, having an aggregate offering price of up to $50.0 million (the “Placement Shares”), pursuant to the Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), on August 24, 2022, (the “Registration Statement”), the related base prospectus (the “Base Prospectus”), and the accompanying prospectus supplement (the “Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”), filed with the SEC pursuant to Rule 424(b) under the Act, and the At Market Issuance Sales Agreement dated August 24, 2022 by and among the Company and B. Riley Securities, Inc. and BTIG, LLC, as agents and principals (the “Sales Agreement”).
 
In connection with this opinion letter, we have examined the Registration Statement, the Prospectus, the Sales Agreement, and originals, or copies certified or otherwise identified to our satisfaction, of the Eighth Amended and Restated Certificate of Incorporation, as amended and the Third Amended and Restated Bylaws of the Company, and such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.
 
We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies.
 
Based upon the foregoing, we are of the opinion that the Placement Shares have been duly authorized by the Company and, when issued and sold by the Company and delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Sales Agreement, will be validly issued, fully paid and non-assessable.
 
The opinions expressed herein are limited to the Delaware General Corporation Law. It is further understood that this opinion is to be used only in connection with the offer and sale of Placement Shares while the Registration Statement is effective under the Securities Act.
 
We hereby consent to the use of this opinion as Exhibit 5.2 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the SEC thereunder.
 

Very truly yours,

/s/ DLA Piper LLP (US)

DLA Piper LLP (US)

 EX-99.1 3 ny20005031x2_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
 
•
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101
•
Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT

FLORHAM PARK, N.J., August 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) to provide up to a $35.0 million term loan.

“We are pleased to partner with Horizon, a leading specialty finance company that has an extensive history of supporting innovative life science companies,” said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. “We anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company’s clinical pipeline.  We look forward to our meeting with the U.S. Food and Drug Administration this quarter to discuss the registrational trial design for our lead program.”

As part of the financing, PDS Biotech received an initial tranche of $25 million at the close. The Company has an option to receive an additional $10 million. Each advance of the loan will be repaid in 48 monthly payments consisting of 24 monthly payments of interest only, followed by 24 monthly payments of principal and accrued interest. In connection with the financing, PDS Biotech issued Horizon warrants to purchase up to 4% of the loan amount, 381,625 of its common shares at an exercise price of $3.6685 per share. Proceeds will be used to support the ongoing clinical development of PDS0101 and other product candidates within the company’s pipeline and for general working capital purposes.

Further information with respect to the debt financing agreement with Horizon will be contained in a current report to be filed on Form 8-K by PDS Biotechnology with the Securities and Exchange Commission.

Conference Call and Webcast
The conference call is scheduled for Thursday, August 25, 2022 at 8:00 AM EDT. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and reference conference ID 13732262. To access the webcast, please use the following link. The event will be archived in the investor relations section of PDS Biotech’s website for six months. 
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located in Portland, Maine, Austin, Texas, and Reston, Virginia. To learn more, please visit www.horizontechfinance.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune™ based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune™ based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including record inflation, unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19 and the ongoing military conflict between Russia and Ukraine. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
 
Nicole Jones
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital








 EX-101.SCH 4 pdsb-20220824.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pdsb-20220824_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 pdsb-20220824_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 24, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 24, 2022
Entity File Number 001-37568
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Central Index Key 0001472091
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 25B Vreeland Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 800
Local Phone Number 208-3343
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
XML 8 ny20005031x2_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2022-08-24 2022-08-24 false 0001472091 NASDAQ 8-K 2022-08-24 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 25B Vreeland Road Suite 300 Florham Park NJ 07932 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - ny20005031x2_8k.htm 11 ny20005031x2_8k.htm ny20005031x2_ex5-1.htm ny20005031x2_ex99-1.htm pdsb-20220824.xsd pdsb-20220824_lab.xml pdsb-20220824_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ny20005031x2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ny20005031x2_8k.htm" ] }, "labelLink": { "local": [ "pdsb-20220824_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20220824_pre.xml" ] }, "schema": { "local": [ "pdsb-20220824.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20220824", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20005031x2_8k.htm", "contextRef": "c20220824to20220824", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20005031x2_8k.htm", "contextRef": "c20220824to20220824", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001140361-22-030756-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-030756-xbrl.zip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end